- Home
- RNTX vs PULM Comparison
RNTX vs PULM Comparison
Compare RNTX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- PULM
- Stock Information
- Founded
- RNTX 2001
- PULM 2003
- Country
- RNTX United States
- PULM United States
- Employees
- RNTX N/A
- PULM N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- RNTX Health Care
- PULM Health Care
- Exchange
- RNTX Nasdaq
- PULM Nasdaq
- Market Cap
- RNTX 40.3M
- PULM 33.2M
- IPO Year
- RNTX N/A
- PULM N/A
- Fundamental
- Price
- RNTX $1.45
- PULM $6.55
- Analyst Decision
- RNTX
- PULM
- Analyst Count
- RNTX 0
- PULM 0
- Target Price
- RNTX N/A
- PULM N/A
- AVG Volume (30 Days)
- RNTX 37.4K
- PULM 59.3K
- Earning Date
- RNTX 08-13-2025
- PULM 08-12-2025
- Dividend Yield
- RNTX N/A
- PULM N/A
- EPS Growth
- RNTX N/A
- PULM N/A
- EPS
- RNTX N/A
- PULM N/A
- Revenue
- RNTX N/A
- PULM $1,921,000.00
- Revenue This Year
- RNTX N/A
- PULM N/A
- Revenue Next Year
- RNTX N/A
- PULM $134.88
- P/E Ratio
- RNTX N/A
- PULM N/A
- Revenue Growth
- RNTX N/A
- PULM N/A
- 52 Week Low
- RNTX $1.33
- PULM $1.78
- 52 Week High
- RNTX $4.40
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- PULM 42.38
- Support Level
- RNTX N/A
- PULM $6.28
- Resistance Level
- RNTX N/A
- PULM $6.96
- Average True Range (ATR)
- RNTX 0.00
- PULM 0.48
- MACD
- RNTX 0.00
- PULM -0.07
- Stochastic Oscillator
- RNTX 0.00
- PULM 16.78
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).